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Preoperative versus postoperative initiation of
thromboprophylaxis following major orthopedic
surgery: safety and efficacy of postoperative




In European countries, low-molecular-weight heparin is generally initiated preoperatively for thromboprophylaxis in
hip or knee replacement surgery. The objective of this review is to compare pre- and postoperative
thromboprophylaxis strategies using available evidence, and discuss the challenges and issues that arise. Surgery is
the first step in the process of thrombus formation, but thrombosis is not an instant process and the formation
and growth of the thrombus can take several days or weeks. Hence, it may be possible to stop this process if
thromboprophylaxis is initiated after surgery. Meta-analyses or systematic reviews comparing pre- and
postoperative initiation of therapy have found no consistent differences in efficacy and similar safety (bleeding
rates) between the two strategies. The recently available oral anticoagulant dabigatran etexilate provides
thromboprophylaxis when administered postoperatively and is as safe as preoperative enoxaparin. Further support
for the use of postoperative oral thromboprophylaxis in hip or knee replacement surgery has been provided by
the phase III clinical trials of rivaroxaban and apixaban versus preoperative enoxaparin. Postoperative
thromboprophylaxis offers the opportunity to change management practices in Europe. As postoperative initiation
may have a clinical benefit in some settings (e.g. for neuraxial anesthesia) and practical advantages (e.g. allowing
same-day admission), it is a worthwhile thromboprophylactic strategy for hip or knee replacement surgery.
Keywords: Thromboprophylaxis, Hip replacement surgery, Knee replacement surgery, Anticoagulation, Dabigatran
etexilate, Rivaroxaban, Apixaban
Introduction
Venous thromboembolism (VTE) is a serious complication
of elective hip and knee replacement surgery. Without
thromboprophylaxis, VTE occurs in approximately 40-
60% of cases. Hence, evidence-based guidelines recom-
mend thromboprophylaxis for all patients undergoing hip
or knee replacement surgery [1,2].
In many European countries, low-molecular-weight
heparin (LMWH) is considered the standard therapy for
prophylaxis following hip or knee replacement surgery
and is initiated preoperatively to maximize efficacy [3].
Preoperative thromboprophylaxis is initiated on the
assumption that the surgery itself and the accompanying
immobility are the main causes of thrombosis [4-7].
However, as most thrombi develop postoperatively, start-
ing anticoagulant therapy following surgery could also
prevent VTE [8-10].
Initiation of thromboprophylaxis after surgery has sev-
eral potential advantages. It simplifies same-day admission
for elective procedures and, as therapy is initiated after
surgery when patients are hemodynamically stable, there
is a lower risk of bleeding. Neuraxial anesthesia is increas-
ingly used in orthopedic surgery, but there is a risk of
spinal hematoma and subsequent paralysis, which could
be increased by the sustained use of an anticoagulant [11].
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Initiation of thromboprophylaxis with LMWH too close to
the start of surgery (from -2 h to +4 h of surgery) is asso-
ciated with an increased risk of bleeding and neuraxial
compressive hematoma, so delaying thromboprophylaxis
until after a stable clot has been established at the injec-
tion site would seem sensible [5,12,13]. The timing of dos-
ing would be dependent upon the onset time (tmax) of the
anticoagulant used [13]. In acknowledgement of the
increased risk of hematoma associated with preoperative
thromboprophylaxis, recent guidelines from the American
Society of Regional Anesthesia and Pain Medicine recom-
mend that needle placement should occur at least 10 to 12
h after a preoperative LMWH dose so that the procedure
it not carried out during peak anticoagulant activity [14].
With postoperative initiation of thromboprophylaxis, ther-
apy is not initiated until several hours after catheter with-
drawal, which may help to improve the safety of neuraxial
blockade [1].
A further aspect of preoperative thromboprophylaxis is
that considerable care must be taken with patients with
impaired renal function to ensure that they are not put at
an increased risk of perioperative bleeding as a result of
the reduced renal excretion of LMWH, subsequent
increased half-life and potential drug accumulation
[15-18].
The advent of oral anticoagulants that provide effective
thromboprophylaxis when initiated postoperatively (e.g.
dabigatran etexilate, rivaroxaban and apixaban) raises the
question of whether European practice should be recon-
sidered [19-26]. Here, I review the information available
based on phase III data for these three novel anticoagula-
tion agents initiated postoperatively, in comparison with
the standard European regimen of LMWH initiated preo-
peratively, and discuss the challenges and questions that
arise.
Pathophysiology of thrombus formation in orthopedic
surgery
Hemostasis is a normal biological process involving the
coagulation cascade. In essence, damage to a blood vessel
wall initiates hemostasis, leading to activation of platelets
and coagulation factors. Thrombin is central to this pro-
cess and is produced on the surface of the activated plate-
lets. An amplification system leads to additional platelet
and clotting factor activation, and more thrombin produc-
tion. Once produced, without thromboprophylaxis, throm-
bin converts fibrinogen to fibrin, which provides a
structural network for the formation of the clot [27].
VTE occurs due to an imbalance in thrombin activity.
For this to happen, three factors, known as Virchow’s
triad, must be present: vascular injury, alterations in
blood flow, and activation of coagulation [28]. In addi-
tion, other independent risk factors for VTE may be pre-
sent, such as patients being over 70 years of age, having
concomitant medical conditions, and use of general
anesthesia. The latter is implicated as a risk factor as it
reduces blood flow to the lower limbs [29].
The risk of VTE following total knee or hip replace-
ment surgery is especially high as several pro-thrombotic
processes are involved: coagulation activation from tissue
and bone injury; vein dilation or injury with endothelial
damage; vein distortion during surgery; heat due to
cement polymerization in total hip replacement; patient
immobility causing venous stasis; and reduced venous
emptying peri- or post-surgery [30,31]. The scale of this
adverse consequence of hip and knee surgery is demon-
strated by the fact that 50% and 40%, respectively, of all
diagnosed deep vein thromboses (DVT) are located in
the proximal leg veins [9]. While surgery may be the
event that initiates thrombus formation, it is not an
instant process. Formation and growth of the thrombus
can take several days or weeks and requires prolonged
thromboprophylaxis, as discussed in the next section.
Timing of thrombus formation
Several studies have examined the occurrence of sympto-
matic thrombosis following orthopedic surgery and have
concluded that, in general, symptomatic thrombosis pre-
sents after discharge from hospital and is the most com-
mon cause for hospital readmission after hip replacement
[8,32,33]. The proportion of symptomatic VTE events
occurring after discharge from hospital ranges from 35%
to 76% depending on the study and the type of surgery
[32,34]. The incidence of asymptomatic DVT, as demon-
strated by venography, is much higher than that of symp-
tomatic VTE following major orthopedic surgery [35].
A recent retrospective review of 12 studies undertaken in
patients undergoing elective total hip or total knee repla-
cement surgery investigated the relationship between
asymptomatic DVT and the subsequent development of
symptomatic VTE [36]. The 3-month incidence of asymp-
tomatic DVT was 13.2% after total hip replacement and
38.1% after total knee replacement compared with rates of
symptomatic VTE of 2.7% and 1.8%, respectively; i.e. one
symptomatic VTE developed for every five asymptomatic
DVTs after total hip replacement surgery compared with
one symptomatic VTE for every 21 asymptomatic DVTs
after total knee replacement surgery [35].
Regarding the timing of symptomatic VTE, Bjørnarå
et al. report that most symptomatic cases of VTE following
orthopedic surgery occur within 3 months of the opera-
tion, with a median time to occurrence of symptomatic
DVT and pulmonary embolism of 21 and 34 days follow-
ing hip replacement, and of 20 and 12 days, respectively,
following knee replacement [8]. Similarly, Dahl et al.
report development of symptomatic DVT, on average,
27 days after hip replacement and 16 days after knee
replacement, while the RIETE Registry reports a mean
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time to clinically overt pulmonary embolism of 22 ± 16
days in patients undergoing major orthopedic surgery
[9,10]. In addition, the risk of developing symptomatic
VTE lasts for up to 3 months after hip replacement and
up to 1 month after knee replacement [1,8]. Given the evi-
dence suggesting that symptomatic VTE can develop up
to 3 months following surgery and that there are large
numbers of asymptomatic DVTs that could become symp-
tomatic, thromboprophylactic treatment for up to 35 days
post-surgery is recommended [1]. Several studies show
that the onset of asymptomatic VTE can also occur several
weeks after total hip replacement; about 20-30% of those
who had no DVT detectable by venography at 7 or 10
days post-surgery (when prophylaxis was stopped) had evi-
dence of asymptomatic DVT on their venograms at weeks
4 to 5 after surgery [13,36-39]. Furthermore, thrombopro-
phylaxis has been shown to reduce the incidence of
asymptomatic and symptomatic VTE, and a longer dura-
tion of prophylaxis provides greater protection than a
shorter duration [40-42].
Preoperative initiation of thromboprophylaxis
The initial trials of LMWH showed an increase in bleeding
if the first dose of 5000 or 2500 U was given 2 h preopera-
tively [43]. However, subsequent European trials have
demonstrated the safety and efficacy of LMWH for pre-
venting VTE following hip and knee replacement surgery
when initiated 12 h preoperatively [44]. Hence, the regi-
men in Europe is generally to administer LMWH once
daily (qd), starting 12 h before surgery, which may reflect
the European preference for single-daily dosing.
The rationale behind this approach is based on the
assumption that the surgical procedure and associated
immobility is the main initiator of thrombosis; administer-
ing prophylaxis before surgery could, therefore, allow opti-
mal antithrombotic treatment [4-7]. However, as already
discussed, the majority of thrombi are formed days, if not
weeks, after surgery and would still be prevented if the
first dose was delayed until after the operation [8-10]. In
addition, initiating therapy 12 h before surgery means that
much of the drug has been eliminated by the time of sur-
gery. For example, the elimination half-life of enoxaparin
sodium is ~4 h after a single subcutaneous (sc) dose and
~7 h after repeated dosing; significant anti-factor Xa activ-
ity persists in plasma for ~12 h following a 40-mg single
sc dose, while the steady state is achieved on the second
day of treatment [45]. This can be viewed as beneficial as
it reduces the risk of intraoperative bleeding, but one
could also argue that the antithrombotic effect is minimal
and the majority of the protective effect comes from sub-
sequent doses given after surgery. Thus, this calls into
question the value of preoperative administration of pro-
phylactic anticoagulants.
Postoperative initiation of thromboprophylaxis
In the USA and Canada, more emphasis has traditionally
been placed on the risk of bleeding than on efficacy when
considering prevention of VTE [46]. Indeed, the 7th edi-
tion of the American College of Chest Physicians (ACCP)
guidelines state: ‘...we place ... a relatively high value on
minimizing bleeding complication’ [47]. An influential
trial of LMWH twice daily (bid) initiated postoperatively
versus placebo was performed by Turpie et al. and showed
effective thromboprophylaxis without excessive bleeding
[48]. As a result, most subsequent US trials investigated
postoperative initiation of thromboprophylaxis, thereby
establishing its efficacy and safety [44]. Consequently,
standard practice in North America is to administer ther-
apy (30 mg enoxaparin bid) starting 12-24 h postopera-
tively once hemostasis has been established.
The timing of therapy initiation with this approach
addresses concerns regarding bleeding, while use of a lar-
ger total daily dose recognizes that some thrombi may
already have formed and that their growth may be slowed,
enabling fibrinolysis [49]. The adoption of the bid regimen
was further driven by the initial approval of LMWH given
by the regulatory agencies, which was based on the half-
life of LMWH [45]. The accumulated data from the US
experience with LMWH support postoperative initiation
of thromboprophylaxis as a safe, effective and convenient
regimen.
Preoperative initiation vs. postoperative initiation of
thromboprophylaxis
The historical data suggest that both preoperative initia-
tion and postoperative initiation of thromboprophylaxis
are safe and effective regimens. Meta-analyses or systema-
tic reviews comparing pre- and postoperative initiation of
therapy have found no consistent difference in efficacy
and safety (bleeding rates) between the two strategies
[5,44,50]. However, the limitations common to all meta-
analyses or systematic reviews and specific to these ana-
lyses (e.g. small sample sizes in some studies, differences
in study conduct, etc.) mean that these studies can only
provide an indication of relative efficacy and safety of the
two strategies. Well-designed studies with large sample
sizes directly comparing the two strategies provide more
robust evidence. Data generated during the development
of dabigatran etexilate, rivaroxaban and apixaban provide
these kind of head-to-head data, and give an insight into
the benefit: risk ratio of these novel anticoagulants
initiated postoperatively compared with the European
standard dose of enoxaparin started preoperatively.
Dabigatran etexilate was studied as thromboprophy-
laxis following elective total knee and hip replacement
surgery in three European trials (Table 1) [19-21]. In all
three studies, oral dabigatran etexilate was initiated as a
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half-dose 1-4 h post-surgery (as long as patients showed
good hemostasis) and continued by using the full dose qd
from the following day onwards. Reducing the first dose
of dabigatran etexilate on the day of surgery with the full
dose thereafter has been shown to improve the safety
profile of the anticoagulant [51]. The comparator was
40 mg sc qd enoxaparin initiated 12 h before surgery.
The end-point in the three studies was a composite of
the incidence of total VTE and all-cause mortality, while
the main safety outcome were the occurrence of bleeding
events defined according to accepted guidelines [52].
Both doses of dabigatran etexilate tested (150 and
220 mg) had similar efficacy and safety to enoxaparin
40 mg (Table 1). Thus, as anticipated, bleeding rates
were comparable between dabigatran etexilate and enox-
aparin, while initiating dabigatran etexilate therapy post-
surgery also effectively prevented or inhibited the process
of clot formation.
Support for the value of postoperative prophylaxis is
also provided by studies comparing oral rivaroxaban 10
mg qd administered 6-8 h following surgery with enoxa-
parin 40 mg sc qd administered preoperatively (Table 2)
[22-24]. It should be noted that rivaroxaban is adminis-
tered a little later after wound closure than dabigatran
etexilate (1-4 h). While postoperative initiation was effec-
tive, a major limitation to evaluating the comparative
safety of rivaroxaban is the unique bleeding definition
used in the studies [22-24]. Analyses of the complete riv-
aroxaban program with a more sensitive composite
bleeding end-point (major bleeding plus clinically rele-
vant non-major bleeding, as used in other trials) showed
a significant higher bleeding rate for rivaroxaban com-
pared with enoxaparin (3.2 vs. 2.5%; P = 0.039 [53]; 3.1
vs. 2.5%; P = 0.049) [53]. This is the expected profile of a
relatively high-dose anticoagulant that provides greater
efficacy compared with enoxaparin therapy at a cost of a
Table 1 Efficacy and safety data from the three trials comparing dabigatran etexilate with the European enoxaparin
dose as thromboprophylaxis following elective total hip or knee replacement surgery [19-21]
220 mg dabigatran etexilate
initiated post-surgery
150 mg dabigatran etexilate
initiated post-surgery
40 mg enoxaparin initiated
12 h pre-surgery
RE-MODEL™trial (knee replacement)
Total VTE and all-cause mortality
(primary efficacy end-point)
183/503 (36.4%) 213/526 (40.5%) 193/512 (37.7%)
Major bleeding 10/679 (1.5%) 9/703 (1.3%) 9/694 (1.3%)
RE-NOVATE® trial (hip replacement)
Total VTE and all-cause mortality
(primary efficacy end-point)
53/880 (6.0%) 75/874 (8.6%) 60/897 (6.7%)
Major bleeding 23/1146 (2.0%) 15/1163 (1.3%) 18/1154 (1.6%)
RE-NOVATE® II trial (hip replacement)
Total VTE and all-cause mortality
(primary efficacy end-point)
61/792 (7.7%) - 69/785 (8.8%)
Major bleeding 14/1010 (1.4%) - 9/1003 (0.9%)
VTE venous thromboembolism
Table 2 Efficacy and safety data from the three trials comparing rivaroxaban with the European enoxaparin dose as
thromboprophylaxis following elective total hip or knee replacement surgery [22-24]
10 mg rivaroxaban initiated post-
surgery
40 mg enoxaparin initiated 12 h pre-
surgery
RECORD1 trial (hip replacement)
Total VTE and all-cause mortality (primary efficacy end-
point)
18/1595 (1.1%) 58/1558 (3.7%)
Major bleeding 6/2209 (0.3%) 2/2224 (0.1%)
RECORD2 trial (hip replacement)*
Total VTE and all-cause mortality (primary efficacy end-
point)
17/864 (2.0%) 81/869 (9.3%)
Major bleeding 1/1228 (0.08%) 1/1229 (0.08%)
RECORD3 trial (knee replacement)
Total VTE and all-cause mortality (primary efficacy end-
point)
79/824 (9.6%) 166/878 (18.9%)
Major bleeding 7/1220 (0.6%) 6/1239 (0.5%)
VTE venous thromboembolism
*In RECORD2, rivaroxaban was given for 31 to 39 days, while enoxaparin was given for 10 to 14 days
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greater risk of bleeding, and is a feature of the therapy
rather than the timing of administration. However, in the
same analysis, dabigatran etexilate showed no differences
in bleeding rates compared with enoxaparin treatment,
underlining the safety of this molecule [54].
Two phase III apixaban trials compared oral apixaban
2.5 mg bid started 12-24 h after orthopedic surgery with
enoxaparin 40 mg sc qd administered 12 h preoperatively
(Table 3) [25,26]. Both trials demonstrated that apixaban
was more effective than the European enoxaparin regi-
men for the primary efficacy outcome and there was no
significant difference in the rate of major or clinically
relevant bleeding [25,26]. Thus, these results also support
the use of postoperative rather than preoperative admin-
istration of thromboprophylactic agents after major
orthopedic surgery.
Implications
Studies comparing pre- and postoperative initiation of
thromboprophylaxis show no advantage of preoperative
over postoperative initiation. The historic experience
together with the evidence gathered in the development
of the novel oral anticoagulants dabigatran etexilate, riv-
aroxaban and apixaban has confirmed that postopera-
tively administered thromboprophylaxis is an efficacious
and safe regimen.
Postoperative initiation of thromboprophylaxis with
dabigatran etexilate, rivaroxaban or apixaban offers sev-
eral benefits, including flexibility with regard to same-day
admission and choice of anesthesia. On a practical level,
because the actual time at which an operation may be
initiated is uncertain (e.g. affected by preparation time,
delays from previous surgical cases), it may be difficult to
ensure that a dose given preoperatively provides adequate
coverage during the operation itself. Additionally, admin-
istration 12 h prior to an operation may require waking
patients from their sleep, which they may find disturbing
and prevent them from resting before the operation.
A frequently asked question is whether or not a
patient is adequately anticoagulated if they ‘lose’ the first
oral dose due to postoperative vomiting. Analyses of
pooled data from the phase III trials of dabigatran etexi-
late showed no significant difference in efficacy between
patients who received the first dose (as a half-dose) 1-4
h post-surgery compared with those who received a
delayed first dose (either a half-dose > 4 h post-surgery
or the full dose the day after surgery) [55].
Conclusion
In summary, the direct thrombin or factor Xa inhibitors
dabigatran etexilate, rivaroxaban and apixaban, adminis-
tered postoperatively, are at least as effective as preo-
perative enoxaparin and have a similar risk of major
bleeding to enoxparin. The availability of these new,
oral, postoperatively administered agents is likely to
challenge the current practice of preoperative initiation
of anticoagulant therapy in many European countries.
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